{'fraction_non_alphanumeric': 0.048599670510708404, 'fraction_numerical': 0.023887973640856673, 'mean_word_length': 5.295336787564767, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hypoglycaemic activity of Geranium core‐core, Oxalis rosea and Plantago major extract in rats

The hypoglycaemic activity of ‘Core‐core’ (Geranium core‐core, Geraniaceae), ‘Culle’ (Oxalis rosea, Oxalidaceae) and ‘Llantén’ (Plantago major, Plantaginaceae) crude extracts was assessed in normoglycaemic rats. Furthermore, the hypoglycaemic activity of Core‐core extract was evaluated in alloxan‐diabetic rats. A single oral dose of 500 mg/kg Core‐core extract significantly reduced glycaemia in normal rats under glucose tolerance test conditions (p < 0.01), while Culle and Llantén were devoid of activity. The effect was lower than a single oral dose of 100 mg/kg tolbutamide. After 7 days oral treatment at 250 mg extract/kg body weight, Core‐core significantly reduced glycaemia (p<0.01) in normal rats under oral glucose tolerance conditions. In alloxan‐diabetic rats, a single oral dose of 500 mg/kg and chronic treatment at 250 mg/kg Core‐core extract significantly reduced glycaemia in glucose tolerance test conditions at p < 0.05 and p < 0.01, respectively. During the acute oral toxicity study, animals treated with Core‐core extract exhibited no symptoms of drug‐induced toxicity with doses up to 5 g/kg.